How would you approach treatment for a patient with a residual disease after resection of a solitary jejunal myeloblastic sarcoma?

Myeloid sarcoma (historically- chloroma or granulocytic sarcoma) is simply an extramedullary form of AML. The majority of patients who present de novo with a myeloid sarcoma will either have bone marrow involvement at diagnosis or will develop such metachronously if systemic therapy is not pursued. ...

Isolated Myeloblastic sarcoma presentation is associated with a high rate of progression to AML within 1 year and is a poor prognostic factor. It tends to be associated with t(8;21) AML. I would pursue systemic treatment and even consider allo SCT if the patient is a transplant candidate, Aslam et a...